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Abstract 
 
Stimulation of the mineralocorticoid receptor (MR) by aldosterone controls several physiological 
parameters including blood pressure, inflammation or metabolism. We previously showed that 
MR turnover constitutes a crucial regulatory step in the responses of renal epithelial cells to 
aldosterone. Here, we identified Protein Phosphatase 1 alpha (PP1α), as a novel cytoplasmic 
binding partner of MR that promotes the receptor activity. The RT-PCR expression mapping of 
PP1α reveals a high expression in the kidney, particularly in the distal part of the nephron. At the 
molecular level, we demonstrate that PP1α inhibits the ubiquitin ligase Mdm2 by 
dephosphorylation, preventing its interaction with MR. This results in the accumulation of the 
receptor due to reduction of its proteasomal degradation and consequently a greater aldosterone-
induced Na+ uptake by renal cells. Thus, our findings describe an original mechanism involving a 
phosphatase in the regulation of aldosterone signaling and provide new and important insights 
into the molecular mechanism underlying the MR turnover. 
 
 
  
Introduction 
 
The mineralocorticoid hormone aldosterone is considered as a principal endocrine factor involved 
in the regulation of ions homeostasis and blood pressure. Aldosterone mediates its effects through 
the Mineralocorticoid Receptor (MR), a 984 amino acids protein belonging to the steroid/thyroid 
hormone receptor superfamily and deriving from the Nr3C2 gene (Arriza, Weinberger, Cerelli et 
al., 1987,Rogerson, Dimopoulos, Sluka et al., 1999). The MR protein is divided in three domains; 
the N-terminal domain (NTD) involved in the control of the transcriptional activity of the 
receptor; the central DNA-binding domain (DBD) involved in the binding of the specific 
response element found on the promoter of MR target genes; and finally a ligand-binding domain 
(LBD) responsible for the selectivity of hormone binding (Faresse, 2014). Upon hormonal 
activation, MR is translocated into the nucleus either as a homodimer, or associated to the 
Glucocorticoid Receptor (GR) as a heterodimer (Ou, Storring, Kushwaha et al., 2001). In the 
nucleus, MR recruits co-factors to induce the transactivation and regulation of hundreds of target 
genes (Gekle, Bretschneider, Meinel et al., 2014,Verrey, Pearce, Pfeiffer et al., 2000). These 
genes present a palindromic DNA sequence common for GR and MR called glucocorticoid 
response element (GRE) within their promoter (Fuller, Lim-Tio and Brennan, 2000). The ligand 
activation mediates also a proteasomal degradation of MR allowing a rapid turnover of the 
activated receptor and attenuates the transcriptional response to aldosterone (Faresse, Ruffieux-
Daidie, Salamin et al., 2010,Faresse, Vitagliano and Staub, 2012,Yokota, Shibata, Kobayashi et 
al., 2004). 
Among the different tissues expressing MR, the principal cells of the aldosterone sensitive 
distal nephron (ASDN) are the best characterized targets of aldosterone. These cells build a 
polarized epithelium allowing a vectorial transport of ions and water between the urinary apical 
and the interstitial basolateral sides. In these cells, activation of MR by aldosterone enhances the 
electrogenic Na+ and water reabsorption and luminal K+ secretion. These characteristics are 
endorsed mainly by the apical expression of the epithelial sodium channel (ENaC), the renal 
outer medullary potassium channel (ROMK), and the basolateral expression of the Na-K-ATPase 
(Meneton, Loffing and Warnock, 2004). The importance of the MR in ion homeostasis and blood 
pressure control has been demonstrated by either loss-of-function mutations in the Nr3C2 gene, 
causing autosomal dominant pseudohypoaldosteronism type 1 (adPHA1) (Geller, Rodriguez-
Soriano, Vallo Boado et al., 1998) or gain-of-function mutations leading to a severe inherited 
form of early-onset hypertension, which is exacerbated during pregnancy (Geller, Farhi, 
Pinkerton et al., 2000). Other pathologies as renal and cardiac injuries (Luther, Luo, Wang et al., 
2012), cerebral aneurysm formation (Tada, Yagi, Kitazato et al., 2010), chorioretinopathy (Zhao, 
Celerier, Bousquet et al., 2012), and epidermis abnormalities (Farman, Maubec, Poeggeler et al., 
2010) have been shown to be associated also with an over-activation of MR signaling. In this 
context, numerous clinical studies demonstrated the efficiency of MR antagonists in the 
prevention of disease progression (Pitt, Zannad, Remme et al., 1999,Bolignano, Palmer, 
Navaneethan et al., 2014,Weinberger, Roniker, Krause et al., 2002). Therefore, the maintenance 
of the body homeostasis is closely related to a tight regulation of MR signaling that occurs at the 
level of ligand availability, the co-factors, the MR nucleo-cytoplasmic shuttling, the cross-talk 
with additional signaling pathways and finally the post-translational modifications (PTMs) of the 
receptor. We previously demonstrated in renal epithelial cells that aldosterone stimulates a rapid 
phosphorylation of MR via ERK1/2 that is critical for MR ubiquitylation state and turnover 
(Faresse et al., 2012). In addition, it was described that the specific S843 phosphorylation of MR, 
occurring exclusively in intercalated cells of the nephron, corresponds to a switch of the 
aldosterone response from K+ secretion to Na+ reabsorption by the kidney (Shibata, Rinehart, 
Zhang et al., 2013). However, the molecular mechanisms characterization of this modification is 
still puzzling and was suggested to involve the kinase WNK4 and the protein phosphatase 1 
(PP1) (Shibata et al., 2013).  
The PP1 holoenzyme consists of a catalytic subunit (PP1c) and one or more co-factors. 
PP1c has four isoforms: PP1α (encoded by ppp1CA), PP1β (encoded by ppp1CB) and PP1γ1 and 
γ2 (splice variants of ppp1CC). These isoforms share a high degree of homology and their 
specificity is dependent on their co-factors, although the isoforms themselves may also drive 
these interactions and influence the substrate selection (Ceulemans and Bollen, 2004,Chiang, 
Heck, Dobrev et al., 2016). Expression and/or activity of several steroid receptors, such as the 
androgen receptor, the pregnane X receptor or the estrogen receptor- α have been shown to be 
regulated by PP1α (Liu, Han, Gulla et al., 2016,Sugatani, Hattori, Noguchi et al., 2014,Bollig, 
Xu, Thakur et al., 2007). In this study, we identified PP1α as a novel MR binding protein that 
stabilizes the expression and the activity of the receptor. We investigated the basis of this 
mechanism and found that the ubiquitin ligase Mdm2, responsible for the MR ubiquitylation and 
degradation, is dephosphorylated and inactivated by PP1α. Thus, PP1α defines a new component 
of the aldosterone signaling that enhances aldosterone stimulation through controlling MR 
expression levels and consequently the Na+ uptake by renal epithelial cells. 
  
Results 
 
PP1α binds to cytoplasmic MR in renal epithelial cells 
To assess the organ distribution of PP1α, a qRT-PCR analysis was performed to evaluate PP1α 
mRNA expression levels in different tissues of normal mice (Figure 1A). We found that PP1α 
expression was high in lung, kidney and white adipose tissue, and very low or undetectable in 
spleen, muscle and pancreas (Figure 1A). To estimate the expression of PP1α in renal epithelial 
cells, we isolated mRNA from freehand microdissected tubules from mouse kidneys. We found 
that PP1α is highly expressed in the distal part of the nephron, including the distal convoluted 
tubule (DCT) and the collecting system (CS), tubules segments showing also the highest 
expression of MR and designated as the aldosterone-sensitive distal nephron (Figure 1B). Based 
on previous studies showing that PP1α interacts and regulates certain steroid receptors (Liu et al., 
2016,Sugatani et al., 2014,Bollig et al., 2007), we hypothesized that PP1α may interact also with 
MR in renal epithelial cells. To verify this hypothesis, we cotransfected S-tagged MR and 
analyzed its association with Flag-tagged PP1α in HEK-293 cells. As shown in Figure 2A, MR 
co-immunuprecipitated with PP1α, and this interaction was decreased by aldosterone treatment. 
Due to the lack of suitable antibody for immunoprecipitation of non-tagged proteins, we 
confirmed the endogenous interaction between MR and PP1α by proximity ligation assay (PLA) 
in mouse cortical collecting duct cells (mCCDcl1). To validate this assay, we first showed that co-
transfection of MR and PP1α in HEK-293 cells resulted in a prominent PLA signal in the 
cytoplasm (Figure 2B bottom); and omission of transfected PP1α plasmids resulted in the 
absence of signal (Figure 2B top). This association was also confirmed endogenously in 
mCCDcl1 cells, since MR and PP1α provided a PLA signal in the cytoplasm that was reduced by 
aldosterone stimulation (Figure 2C). Quantitative analysis demonstrated that PLA signal was 
significantly reduced (about 50%) when mCCDcl1 cells were treated with aldosterone (Figure 
2D). 
 
PP1α activity prevents MR proteasomal degradation 
As PP1α has been shown to regulate the expression of certain steroid receptors, we tested 
whether this phosphatase controls also MR stability. To answer this question, we used 
tautomycin, a potent and specific pharmacological inhibitor of PP1 (Swingle, Ni and Honkanen, 
2007). Treatment of mCCDcl1 cells with tautomycin induced a dramatic decrease in endogenous 
MR expression in a dose dependent manner, without affecting the expression of PP1α (Figure 
3A). We also demonstrated that this effect is time dependent (Figure 3B). To ascertain the 
specific effect of PP1α, we showed that overexpression of increasing amounts of PP1α produced 
a dose-dependent increase in the expression level of MR (Figure 3C). Furthermore, the co-
transfection of I1, an endogenous inhibitor of PP1, completely abolished the PP1α-induced 
stabilization of MR, and reduced the level of the receptor (Figure 3D). The tautomycin-dependent 
decrease of steroid receptors expression has been reported to involve the ubiquitin/proteasome 
system (Liu et al., 2016). We confirmed these observations by showing that PP1α inhibition 
increased the polyubiquitylation of MR (Figure 3E) and inhibition of the proteasome by MG132 
prevented the tautomycin-induced degradation of endogenous MR (Figure 3F). These data 
suggested that PP1α binding to the receptor may prevent the induction of MR polyubiquitylation 
and degradation. It has been described that PP1α binds to its substrates via the consensus docking 
motif partners, R/K-x(0,1)-V-x-F (Garcia, Cayla, Caudron et al., 2004). The DNA-binding 
domain of MR presents a conserved potential PP1α consensus binding motif KVFF (Figure 4A). 
To investigate the potential role of this motif, we mutated the essential residues V625 and F627 
to alanine (KVFF to KAFA). We found that the mutation has no effect on MR nuclear 
translocation after aldosterone stimulation (Figure 4B). We also found that mutated MR 
preserved its ability to interact with the receptor and that aldosterone reduced this association 
(Figure 4C). Finally, the MR mutant was stabilized by PP1α in a similar manner to the wild-type 
form (Figure 4D). Taken together, these data suggested that PP1α binds to MR and stabilizes its 
expression independently of the substrate recognition sequence KVFF. 
 
PP1α stabilizes MR expression by reducing Mdm2 activation 
To investigate the molecular mechanisms explaining the MR stabilization by PP1α, we focused 
on the ubiquitin ligase Mdm2. This enzyme has been shown to induce the degradation of several 
steroid receptors (Liu et al., 2016,Sengupta and Wasylyk, 2001,Duong, Boulle, Daujat et al., 
2007,Heyne, Heil, Bette et al., 2015) and its activity is regulated by PP1α (Liu et al., 2016,Lee, 
Lim, Min et al., 2007). To confirm the role of PP1α on Mdm2 activity, we evaluated the 
activating phosphorylation occurring on the residue S166. We found that inhibition of PP1α by 
tautomycin led to an increase of endogenous Mdm2 phosphorylation in renal epithelial cells 
(Figure 5A). Conversely, overexpression of PP1α induced a decrease of S166 phosphorylation 
levels (Figure 5B). Then, we tested whether Mdm2 interacts with MR and if PP1α activity 
regulates this association. Using the PLA, we found that endogenous Mdm2/MR association was 
small in control conditions, while treatment with tautomycin increased significantly this 
interaction (Figure 5C and D). This observation suggested that PP1α activity prevents the 
recruitment of Mdm2 to MR. To test whether MR is a substrate for Mdm2, we first demonstrated 
by immunoprecipitation experiments that Mdm2 increased the polyubiquitylation of MR (Figure 
5E). This modifications reduced MR expression, since co-transfection of MR with an increasing 
dose of Mdm2 reduced MR expression level in a dose dependent manner (Figure 5F). However, 
over-expression of PP1α abrogated completely the effects of Mdm2 and restored the MR 
expression (Figure 5G). Similarly, inhibition of Mdm2 activity by Nutlin-3, abolished the 
tautomycin induced degradation of MR (Figure 5H). All together, we demonstrated that PP1α 
activity prevents the binding of Mdm2 to MR and consequently the polyubiquitylation and 
degradation of the receptor. 
 
The cellular responses to aldosterone are enhanced by PP1α 
Given that PP1α stabilizes the expression level of MR, we questioned whether PP1α affects also 
its activity. We first showed that stabilization of MR by PP1α increased the presence of MR in 
the nucleus, both at basal and after aldosterone stimulation (Figure 6A). Conversely, treatment 
with tautomycin abrogated totally the aldosterone nuclear accumulation of MR (Figure 6A). The 
higher accumulation of MR in the nucleus suggested that PP1α affects the transcription of target 
genes. To verify this hypothesis, we examined whether PP1α could influence MR transcription 
by luciferase assay using the aldosterone-responsive reporter gene mouse mammary tumor virus 
(MMTV)-luc. Consistent with the nuclear accumulation of MR, PP1α overexpression resulted in 
a significant increase of the basal as well as the aldosterone-dependent transcription (Figure 6B). 
To test the effect of PP1α on the intrinsic transcriptional activity of MR and its ligand affinity, we 
performed a luciferase assay using several doses of aldosterone. We found that PP1α 
overexpression affected slightly but significantly the affinity of MR to aldosterone (IC50: MR= 
0.19nM ±0.05; MR+PP1α= 0.08nM ±0.02, p value=0.02) (Figure 6C). As these PP1α effects 
were assumed to be related to Mdm2 inhibition, we performed a similar experiment by co-
transfecting Mdm2. We found that Mdm2 reduced significantly the transcriptional activity of 
MR, and this inhibition was relieved by co-transfection of PP1α (Figure 6D). To investigate the 
endogenous significance of PP1α in renal epithelial cells, we followed the synthesis of the 
aldosterone-induced gene Sgk1 in mCCDcl1 cells (Bhargava, Fullerton, Myles et al., 2001). As 
anticipated, Sgk1 mRNA and protein levels were significantly upregulated upon aldosterone 
stimulation and this induction was drastically inhibited by co-treatment with tautomycin (Figure 
6E).  
As the aldosterone-mediated transcription was affected by PP1α, we tested the impact of 
PP1α inhibitor on the aldosterone-stimulated Na+ reabsorption via the epithelial Na+ channel 
(ENaC). In this context, we determined the transepithelial current of polarized mCCDcl1 grown of 
collagen-coated semipermeable filters (Faresse et al., 2010,Gaeggeler, Gonzalez-Rodriguez, 
Jaeger et al., 2005). We found that the increase of Na+ current mediated by aldosterone was 
significantly reduced when cells were co-treated with tautomycin (Figure 7A). The fact that the 
transepithelial resistance (Figure 7B) was not significantly affected by tautomycin treatment 
suggested that the drug did not perturb the epithelial tight junctions. Therefore, the observed 
variations in Na+ flux were likely attributable to variations in the transepithelial transport of Na+. 
Hence, these results suggest that PP1α enhances the cellular response to aldosterone and 
consequently increase the Na+ transport by ENaC in renal epithelial cells. 
 
  
Discussion 
 
Our study proposes PP1α as a novel protein partner of the non-activated cytoplasmic MR. This 
phosphatase stabilizes MR expression and renders the renal epithelial cells more responsive to 
aldosterone stimulation. Interestingly, we found that PP1α is highly expressed in the kidney, 
suggesting a regulatory role of this phosphatase in Na+ handling and consequently in blood 
pressure control. Inhibiting PP1α activity with the pharmacological inhibitor Tautomycin or by 
overexpression of the specific inhibitor I1 reduced both the transfected and the endogenous MR 
expression. At the molecular level, we showed that PP1α inactivates Mdm2 via de-
phosphorylation of the serine 166, reducing the Mdm2-triggered poly-ubiquitylation and 
proteasomal degradation of MR. 
We previously reported that aldosterone activation induces a rapid phosphorylation of MR 
on several serine residues in the NTD (Faresse et al., 2012). These ERK1/2 mediated 
phosphorylations are critical for the aldosterone-induced poly-ubiquitylation and degradation of 
the receptor. However, according to our findings, MR seems not to be a direct substrate of PP1α. 
First, a mutant form of MR, where the consensus docking motif found within PP1α substrates 
was altered, maintained its ability to interact and to be stabilized by PP1α (Figure 4). 
Furthermore, we previously showed that MR phosphorylation is reflected by an increase of the 
apparent molecular weight of the receptor on immunoblots (Faresse et al., 2010,Faresse et al., 
2012). In this study, we found that PP1α activity did not affect the aldosterone induced upward 
shift of MR, indicating an absence of a direct effect on the receptor phosphorylation. However, 
several ERK1/2-independent phosphorylation sites on MR have been reported (reviewed in 
(Faresse, 2014)). Thus, we cannot exclude a potential direct effect of PP1α on ERK1/2-
independent sites, such as the serine 843 suggested by a previous report using the purified 
proteins MR and PP1 (Shibata et al., 2013). 
The ubiquitin ligase Mdm2 has been shown to control the expression of several steroid 
receptors, such as the glucocorticoid receptor (Sengupta and Wasylyk, 2001), the estrogen 
receptor (Duong et al., 2007), the androgen receptor (Liu et al., 2016), or the vitamin D receptor 
(Heyne et al., 2015). Here we demonstrated that Mdm2 was also able to increase the poly-
ubiquitylation and the degradation of MR, confirming previous reports indicating that Mdm2 may 
play a role in aldosterone signaling. For instance, it was demonstrated that the aldosterone early 
target gene Sgk1 regulates the phosphorylation level of Mdm2 at serine 166 (Amato, D'Antona, 
Porciatti et al., 2009). Furthermore, in vascular smooth muscle cells, it has been shown that 
Mdm2 is a mineralocorticoid-responsive gene involved in aldosterone-induced human vascular 
structural remodeling (Nakamura, Suzuki, Suzuki et al., 2006). However, questions persist about 
the precise physiological conditions promoting MR degradation by Mdm2, which may contribute 
to a negative feedback regulation of aldosterone signaling. In this context, we and others have 
described that ligand stimulation of MR, increases the receptor poly-ubiquitylation and turnover 
(Faresse et al., 2012,Yokota et al., 2004). However, neither the enzymes nor the target lysine 
residues on MR were identified. Here we showed that MR stability was sensitive to Mdm2 and 
given that the kinase Sgk1 regulates Mdm2 activity, this ubiquitin ligase appears to be an 
interesting candidate requiring further characterization in the context of the MR aldosterone-
mediated degradation.  
We report in this study that PP1α is highly expressed in the aldosterone-sensitive distal 
nephron. Furthermore, by interfering pharmacologically with PP1α activity, we were able to limit 
the aldosterone-induced Na+ uptake by cortical collecting duct cells. These findings shed light on 
the potential implication of PP1α in ions homeostasis. The aldosterone-sensitive distal nephron 
reabsorbs 5%-10% of the filtered Na+ (Palmer and Schnermann, 2015). This process is highly 
regulated helping to match urinary Na+ excretion with dietary Na+ intake. Inappropriate Na+ 
reabsorption by the distal nephron is generally associated with altered blood pressure (Lifton, 
Gharavi and Geller, 2001). Several kinases have been described to play a critical role in the 
regulation of signaling pathways and transporters involved in Na+ reabsorption along the ASDN. 
However, only few phosphatases have been linked to renal Na+ handling. It has been shown that 
pharmacological inhibition of the protein phosphatase 3 (Calcineurin) by tacrolimus activates the 
renal sodium chloride cotransporter (NCC) and cause hypertension (Hoorn, Walsh, McCormick 
et al., 2011). Furthermore, genetic ablation of the endogenous PP1 inhibitor I-1 or ex vivo 
incubation of DCTs with the PP1 inhibitor calyculin A drastically affected NCC phosphorylation 
and blood pressure (Sorensen, Grossmann, Roesinger et al., 2013,Picard, Trompf, Yang et al., 
2014).¨The physiological role of PP1 in blood pressure control is corroborated by observations 
done in the heart of transgenic mice over-expressing the active PP1-inhibitor I1. The inhibition of 
PP1 specifically in the heart was associated with enhanced cardiac function and conferred 
protection against heart failure propensity, similarly to what was described clinically with MR 
blockers (Pathak, del Monte, Zhao et al., 2005,Zannad, McMurray, Krum et al., 2011). 
In summary, our findings proposed PP1α as a novel regulator of the aldosterone signaling 
particularly in kidney epithelial cells. This phosphatase renders cells sensitive to aldosterone 
stimulation by maintaining an appropriate pool of the aldosterone receptor MR. To the best of our 
knowledge; this is the first report describing the role of PP1α and its substrate Mdm2 in the 
control of MR expression level. These findings open new perspectives and raise new questions 
about the implication of MR turnover in blood pressure control. 
 
  
Material & Methods 
 
Cell culture 
Mouse cortical collecting duct clone 1 (mCCDcl1) cells were cultured in complete medium 
containing DMEM-F12 (1:1), 5µg/ml insulin, 5µg/ml transferrin, 6×10−8M sodium selenate, 
5×10−8 M dexamethasone, 1nM triiodothyronine, 10ng/ml epidermal growth factor, 10mM 
HEPES, pH 7.4, and 2% FCS. For experiments, cells were seeded and grown in complete growth 
medium on collagen coated Transwell filters for first 5 days, and then grown for another 5 days 
in medium containing DMEM-F12 medium (1:1), 5µg/ml insulin, 6×10−8M sodium selenate, 
3×10−9M dexamethasone, 1nM triiodothyronine, and 10mM HEPES, pH 7,4. Before 
experiments, cells were incubated in minimal medium [DMEM-F12 (1:1)] for overnight and all 
the treatments were done in minimal medium. (Faresse et al., 2010). HEK293T cells were grown 
in DMEM supplemented with 10% FCS. The cells were transfected with lipofectamine following 
the manufacturer`s direction (Invitrogen). 
 
In situ proximity ligation assay: 
MR interaction with PP-1 α and MDM2 were detected by in situ proximity ligation assay (PLA) 
by using commercially available kit (Duolink, Olink Biosciences). HEK293T cells were co-
transfected with Stag-MR wt and FLAG-PP1α. Mouse monoclonal S-tag and Rabbit monoclonal 
PP1α antibodies were used to detect MR and PP1α respectively. In mCCDcl1, we used rabbit 
monoclonal PP1α antibody and mouse MR antibody to detect endogenous MR/PP1α interaction 
in the presence and absence of aldosterone. To detect MR and MDM2 interaction, we used rabbit 
MDM2 and mouse MR antibodies in mCCDcl1 treated or not with tautomycin. For the negative 
controls, either one of the primary antibodies or plasmids were omitted.  Number of fluorescent 
dots were counted per cell visually under fluorescent microscope and expressed as an average 
from 3 independent staining. For this experiment, the low cell confluency allowed a clear 
delimitation of each counted cell. 
 
Plasmids and antibodies 
Expression vectors for the transfected proteins were pcDNA3.1 Stag-MR wt, and the mutant form 
of MR (KAFA) was derived from wild-type (wt) MR by site-directed mutagenesis, Myc-Mdm2, 
FLAG-PP1α and HA-ubiquitin. The antibodies used were anti-MR (1:100) (Gomez-Sanchez, de 
Rodriguez, Romero et al., 2006), anti-PP1α (1:1000 ab52619, Abcam), anti-MDM2 (1:1000, SC-
812, Santa Cruz), anti-P-Mdm2 (1:500, 3521, Cell Signaling), anti-Stag (1:5000, 71549-3, 
Novagen), anti-FLAG FG4R (1:5000, MA1-91878, Thermo Fisher), anti-Myc 4A6 (1:1000, 05-
724, Millipore), anti-HA (1:4000, ab9110, Abcam), anti-SGK1 (1:1000, S5188; Sigma).  
 
Immunoblotting and immunoprecipitation  
Procedures were followed as described previously (Faresse et al., 2012). Briefly, for 
immunoprecipitation, 500µg proteins were incubated overnight at 4°C under rotation with the 
respective antibodies and then incubated with protein G-Sepharose beads (Amersham) at 4°C for 
1 h. For the pull down assay, S-tagged agarose beads (Novagen) were incubated with the lysate at 
4°C for 4 hrs. After five times washing, samples were eluted in 40 µl of 2× Sample Buffer and 
submitted to 8% SDS-PAGE.  
 
Transcriptional reporter assay 
HEK293T cells were seeded on 24-well tissue culture plates then co-transfected by 
Lipofectamine with the reporter gene MMTV-luc (kindly provided by P.J Fuller), the constitutive 
luciferase vector coding for Renilla and the indicated plasmids. After 30h, cells were exposed to 
aldosterone (10 nM) for 16h. After hormone treatment, cells were washed twice with phosphate-
buffered saline (PBS) and lysed with 100 µl of passive lysis buffer (Promega). Luciferase activity 
was determined by using a luciferase kit (Promega). Luciferase activity was normalized for 
constitutive Renilla luciferase. The IC50 and its standard deviation was evaluated by the R 
software using the dose response model LL.4. 
 
Tubules microdissection 
C57BL/6 mice aged between 8-14 weeks were used to map the expression of MR and PP1α along 
the nephron. The harvesting of the kidneys was performed in accordance to Swiss animal welfare 
regulations. Mice were anesthetized by isoflurane inhalation and the kidneys were perfused with 
10 ml DMEM/ F-12 media (Gibco) followed by 4.5mL liberase (0.06 mg/mL; Roche). The 
cortical part was cut into thin horizontal sections and digested in 500µl liberase. After washing 
with ice cold media, segments were manually dissected under stereomicroscope. The tubuli were 
identified on the bases of their respective morphology. Total RNA was isolated using Absolutely 
RNA Nanoprep Kit (Agilent) and 20 ng of total RNA was used to generate cDNA (Superscript 
IV, Thermo Fisher Scientific) using random primers. Each dissected sample was scrutinized for 
its purity using specific gene markers for instance Podocalyxin for Glomeruli, Aminopeptidase N 
(CD 13) for Proximal Tubuli,  NKCC2 for  Thick Ascending Limb, NCC for distal convoluted 
tubuli and Aqp-2 for collecting system and 18s RNA was used as the housekeeping gene. Any 
sample with cross contamination was discarded. The clean samples expressing exclusively their 
respective nephron marker were finally selected. 
 
Real-time quantitative PCR 
Total  RNA  was  extracted  using  the  RNeasy  Mini  Kit  (Qiagen) and was reverse transcribed 
using RevertAidTM cDNA  Synthesis  Kit  (Thermo  Scientific).  Sequences of primers are 
indicated in Table 1.  Quantitative RT-PCR was performed in duplicate for each sample in a 
Light Cycler 480 Real-Time PCR System by using Master I SYBR Green qPCR Master Mix 
(Roche), according to the manufacturer’s instructions. Relative amounts of mRNA were 
determined using the Comparative CT Method for quantification and were normalized to 
GAPDH mRNA expression. 
 
Membrane potential and resistance measurements 
Confluent mCCDcl1 cells were seeded and grown on collagen-coated Transwell filters for the 
measurement of Na+ transport in response to aldosterone. Transepithelial potential difference 
(mV) and transepithelial electrical resistance (Ohm/cm2) were recorded under sterile conditions 
using Millicell-ERS ohmmeter apparatus (Millipore), and the corresponding currents were 
calculated. In each experiment, there were three filters per condition. Before measuring, cells 
were treated or not with tautomycin (100nM for 18 hrs), with or without aldosterone (10nM for 4 
hrs).  
 
Immunofluorescence analysis 
HEK293T cells were transfected with MRWT and MRKAFA. After 48 hrs, cells were treated with 
vehicle or aldosterone (10 nM) for 2 hrs. Afterward, cells were fixed in 4% formaldehyde for 30 
min and permeabilized in 0.1% Triton X-100. Then, the cells were incubated with the anti-MR 
primary antibody overnight at 4°C, followed by the secondary antibody conjugated to FITC for 
1h at room temperature. The coverslips were mounted using mounting medium and then were 
imaged under fluorescence microscope. 
 
Data analysis 
All the experiments were done at least twice, and the representative immunoblots or IF images 
are shown. Experiments were done in triplicate and all data are presented as mean ± S.D and 
were analyzed by unpaired two-tailed Student’s t test. P-values of <0.05 were considered to be 
significant.   
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Figure legends 
 
Figure 1: PP1α is highly expressed in the kidney. (A) The abundance of PP1α mRNA expression 
relative to Gapdh was assessed by qRT-PCR in different organs from 4 mice. (B) The abundance 
of PP1α and MR mRNA expression relative to 18s RNA was assessed by qRT-PCR along the 
nephron. Glomerulus (Glom.), Proximal Tubuli (PT), Descending Limb (DL), Thick Ascending 
Limb (TAL), Distal Convoluted Tubuli (DCT), Collecting System (CS). The values were 
reported to the maximum of expression (DCT for PP1α and CS for MR) ±SD of triplicates. 
 
Figure 2: PP1α interacts with MR in renal epithelial cells. (A) HEK-293 cells were co-
transfected with Stag-MR and Flag-PP1α and treated with vehicle or aldosterone (10nM) for 3h 
before lysis. Cell lysates were immunoprecipitated with anti-Flag and blotted with anti-Stag for 
immunoprecipitation control. Expression level of proteins under investigation was determined by 
direct immunoblotting (Input). Data shown are representative from 2 independent experiments. 
(B) PLA assay detecting MR-PP1α interactions. HEK-293 cells were transfected with MR alone 
or MR+PP1α and fixed. After the PLA reaction, coverslips were mounted in the presence of 
DAPI to counterstain nuclei. (C) PLA assay detecting MR-PP1α interactions on mCCDcl1 cells 
treated with vehicle or 10nM aldosterone. (D) Quantitative analysis of PLA signals in mCCDcl1 
cells from experience (C). Bars represent the means of discrete dots per cells ± SEM (n=80) from 
3 independent stainings, ***P<0.001, control vs. +Aldo. 
 
Figure 3: PP1α prevents MR degradation by the proteasome. (A and B) mCCDcl1 cells were 
treated with an increasing dose of Tautomycin from 50nM to 200nM for 16h, or at indicated time 
with 100nM. Cell lysates were analyzed by immunoblotting using antibodies against MR and 
actin as a loading control. (C) HEK-293 cells were co-transfected with Stag-MR and increasing 
doses of Flag-PP1α. The expression of proteins under investigation was determined by direct 
immunoblotting with anti-Stag or anti-Flag antibodies and actin as a loading control. (D) Stag-
MR, Flag-PP1α were co-transfected with or without Myc-I1 in HEK-293 cells. Cell lysates were 
analyzed by direct immunoblotting with anti-Stag, anti-Flag and anti-Myc antibodies and actin as 
a loading control. (E) HEK-293 cells were co-transfected with Stag-MR and HA-Ub and treated 
with vehicle or Tautomycin (100nM) for 16h and MG132  (10µM the last 6h). Cell lysates were 
submitted to Pull-Down (PD) with Stag agarose beads and the ubiquitylated forms of MR were 
analyzed by immunoblotting with anti-HA antibody. Expression level of MR was determined by 
direct immunoblotting (Input) and actin as loading control. (F) mCCDcl1 cells were treated with 
vehicle or Tautomycin (100nM for 16) in presence or absence of the proteasome inhibitor 
MG132 (10µM for the last 6h). MR expressed was assessed by immunoblot using anti-MR 
antibody and actin as loading control. (A to F) Immunoblots shown are representative from 2-4 
independent experiments. 
 
Figure 4: PP1α binds to MR independently to its KVFF domain. (A) Model representing the 
mutation of the KVFF domain to KAFA on MR. (B) HEK-293 cells were transfected with GFP-
MRwt or GFP-MRKAFA and treated with vehicle or aldosterone (10nM). The localization of the 
two proteins was analyzed by a fluorescence microscope. (C) HEK-293 cells were co-transfected 
with Stag-MRwt or Stag-MRKAFA and Flag- PP1α and treated or not with aldosterone (10 nM) for 
3 h before lysis. Cell lysates were submitted to Pull-Down with Stag agarose beads and blotted 
with anti-Flag for Pull-down control. Expression level of proteins under investigation was 
determined by direct immunoblotting (Input) using Stag or Flag antibodies and actin as loading 
control. (D) HEK-293 cells were transfected with Stag-MRwt or Stag-MRKAFA with or without 
Flag- PP1α. Cell lysates were analyzed by immunoblotting using antibodies against Stag, Flag 
and actin as a loading control. Immunoblots shown are representative from 2 independent 
experiments. 
 
Figure 5: PP1α stabilizes MR by inhibiting Mdm2. (A) mCCDcl1 cells were treated or not with 
Tautomycin (100nM for 16). Cell lysates were analyzed by immunoblotting using antibodies 
against phospho-Mdm2, Mdm2 and actin as a loading control. (B) HEK-293 cells were 
transfected with Flag-PP1α and cell lysates were analyzed by immunoblotting using antibodies 
against phospho-Mdm2, Mdm2, Flag and actin as a loading control. (C) PLA assay detecting 
endogenous MR-Mdm2 interactions in mCCDcl1 cells treated with vehicle or 100nM 
Tautomycin. After the PLA reaction, coverslips were mounted in the presence of DAPI to 
counterstain nuclei. (D) Quantitative analysis of PLA signals in mCCDcl1 cells from experience 
(C) in 3 independent stainings. Bars represent the means of discrete dots per cells ± SEM (n=80), 
***P<0.001, Control vs. Tauto. (E) HEK-293 cells were co-transfected with Stag-MR, HA-Ub 
and Myc-Mdm2 and treated with MG132 (10µM) 6h before lysis. Cell lysates were submitted to 
Pull-Down (PD) with Stag agarose beads and the ubiquitylated forms of MR were analyzed by 
immunoblotting with anti-HA antibody. Expression levels of MR and Mdm2 were determined by 
direct immunoblotting (Input) and actin as loading control. (F) HEK-293 cells were co-
transfected with Stag-MR and increasing doses of Myc-Mdm2. The expression of proteins under 
investigation was determined by direct immunoblotting with anti-Stag or anti-Myc antibodies and 
actin as a loading control. (G) HEK-293 cells were co-transfected with Stag-MR and Myc-Mdm2 
with or without Flag-PP1α. Cell lysates were analyzed by immunoblotting using antibodies 
against Stag, Flag, Myc and actin as a loading control. (H) HEK-293 cells were transfected with 
Stag-MR and treated with Tautomycin (100nM) or Nutlin-3 (20µM) for 16h. Cell lysates were 
analyzed by immunoblotting using antibodies against Stag, Mdm2 and actin as a loading control. 
(A to H) Immunoblots shown are representative from 2-3 independent experiments. 
 
Figure 6: PP1α potentiates the aldosterone-induced transcription. (A) HEK-293 cells were co-
transfected with Stag-MR with or without Flag-PP1α and treated with vehicle or Tautomycin 
(100nM for 16h) or aldosterone (10nM for 3h). Cytoplasmic and nuclear fractions were analyzed 
by immunoblotting with anti-Stag. As controls, the fractions were reprobed for α-GAPDH 
(cytoplasmic) and lamin B (nuclear). Immunoblots shown are representative from 2 independent 
experiments. (B and C) HEK-293 cells were transfected with mouse mammary tumor virus 
(MMTV)-luc, CMV-Renilla, and MR together with PP1α. After 24h of transfection, cells were 
treated with vehicle or 10nM aldosterone (B) or an increasing dose (C) for 16 h; then firefly 
luciferase (from MMTV-luc) was measured and normalized to Renilla. Data are representative of 
2 independent experiments and given as means ± SD of triplicates, ***P<0.001, MR vs. 
MR+PP1α. (D) Same as (B) with co-transfection of Mdm2. (E and F) mCCDcl1 cells were treated 
with or without Tautomycin (100nM for 16h), aldosterone (10nM for 4h). (E) The abundance of 
SGK1 mRNA was measured by qRT-PCR. Data are representative of 2 independent experiments 
in triplicates and given are means relative to GAPDH ± SD (n=3). Cell lysates were also 
subjected to immunoblotting using antibodies against SGK1 and actin as a loading control 
(representative of 3 independent experiments).  
 
Figure 7: PP1α inhibition prevents aldosterone-induced Na+ uptake. mCCDcl1 cells grown on 
collagen-coated permeable filters. Cells were treated with aldosterone 10nM and Tautomycin for 
16h. (A) The transepithelial equivalent short-circuit current was calculated according to Ohm's 
law from the measured values of transepithelial potential difference and resistance (B). Data are 
representative of 3 independent experiments in triplicates. Each bar represents the mean ± SD. 
   
Table-1: Primer sequences used for qRT-PCR analysis   
  
 
Primers  Sequences 
MR fwd AGTTCCTTTCCGCCTGTCAA 
MR rev TGACACCCAGAAGCCTCATC 
PP1α fwd AAGAACGTGCAGCTGACAGA 
PP1α rev GCCATGGATGTCACCACAGAT 
Sgk1 fwd CTCAGTCTCTTTTGGGCTCTTT 
Sgk1 rev TTTCTTCTTCAGGATGGCTTTC 
Gapdh fwd CCATCACCATCTTCCAGGAG 
Gapdh rev TCCATGGTGGTGAAGACAC 
18sRNA fwd GCAATTATTCCCCATGAACG 
18sRNA rev GGGACTTAATCAACGCAAGC 
Podocalyxin fwd ACA CAC AAA CCA TTG GGC AC 
Podocalyxin rev GTG TGG AGA CGG GCA ATG TA 
Aminopeptidase N fwd AATCTCATCCAGGGAGTGACC 
Aminopeptidase N rev GTGGCTGAGTTATCCGCTTT 
NKCC2 fwd GGA ATT GGT CTG GGC GTC A 
NKCC2 rev ATT GAC CCA CCG AAC TCA GG 
NCC fwd TGACCTGCATTCATTCCTCA 
NCC rev GAAGCGAACAGGTTCTCCAG 
Aqp-2 fwd CCGCCATCCTCCATGAGATT 
Aqp-2 rev TGCATTGTTGTGGAGAGCAT 
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